CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 94 filers reported holding CONCERT PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 0.72 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $2,440 | -99.9% | 417,858 | +2.3% | 0.00% | – |
Q3 2022 | $2,736,000 | +166.1% | 408,489 | +67.2% | 0.00% | – |
Q2 2022 | $1,028,000 | +20.5% | 244,373 | -3.5% | 0.00% | – |
Q1 2022 | $853,000 | +5.3% | 253,184 | -1.5% | 0.00% | – |
Q4 2021 | $810,000 | -27.9% | 257,143 | -25.2% | 0.00% | – |
Q3 2021 | $1,123,000 | -17.0% | 343,700 | +7.2% | 0.00% | – |
Q2 2021 | $1,353,000 | -49.6% | 320,622 | -40.5% | 0.00% | – |
Q1 2021 | $2,687,000 | -44.3% | 538,521 | +41.2% | 0.00% | -100.0% |
Q4 2020 | $4,820,000 | +34.4% | 381,367 | +4.4% | 0.00% | 0.0% |
Q3 2020 | $3,587,000 | +1.0% | 365,317 | +2.4% | 0.00% | 0.0% |
Q2 2020 | $3,551,000 | +19.1% | 356,913 | +5.8% | 0.00% | 0.0% |
Q1 2020 | $2,981,000 | -38.7% | 337,280 | -36.0% | 0.00% | 0.0% |
Q4 2019 | $4,860,000 | +236.3% | 527,000 | +114.4% | 0.00% | – |
Q3 2019 | $1,445,000 | -50.9% | 245,764 | +0.2% | 0.00% | -100.0% |
Q2 2019 | $2,944,000 | +7.4% | 245,367 | +8.0% | 0.00% | 0.0% |
Q1 2019 | $2,740,000 | -47.3% | 227,088 | -45.3% | 0.00% | 0.0% |
Q4 2018 | $5,204,000 | +54.7% | 414,794 | +82.9% | 0.00% | 0.0% |
Q3 2018 | $3,365,000 | -1.4% | 226,764 | +11.8% | 0.00% | 0.0% |
Q2 2018 | $3,412,000 | -18.9% | 202,748 | +10.3% | 0.00% | 0.0% |
Q1 2018 | $4,208,000 | -2.9% | 183,795 | +9.7% | 0.00% | 0.0% |
Q4 2017 | $4,334,000 | +125.0% | 167,584 | +28.3% | 0.00% | 0.0% |
Q3 2017 | $1,926,000 | +7.7% | 130,602 | +1.9% | 0.00% | 0.0% |
Q2 2017 | $1,788,000 | -26.6% | 128,182 | -10.2% | 0.00% | 0.0% |
Q1 2017 | $2,435,000 | +66.8% | 142,740 | +0.6% | 0.00% | 0.0% |
Q4 2016 | $1,460,000 | -2.5% | 141,902 | -4.3% | 0.00% | 0.0% |
Q3 2016 | $1,498,000 | -5.0% | 148,228 | +5.5% | 0.00% | 0.0% |
Q2 2016 | $1,577,000 | -17.8% | 140,469 | +0.0% | 0.00% | 0.0% |
Q1 2016 | $1,918,000 | -22.1% | 140,421 | +8.2% | 0.00% | 0.0% |
Q4 2015 | $2,461,000 | +2.9% | 129,779 | +1.9% | 0.00% | 0.0% |
Q3 2015 | $2,391,000 | +70.2% | 127,386 | +34.9% | 0.00% | 0.0% |
Q2 2015 | $1,405,000 | +11.6% | 94,395 | +13.5% | 0.00% | 0.0% |
Q1 2015 | $1,259,000 | +206.3% | 83,148 | +169.4% | 0.00% | – |
Q4 2014 | $411,000 | +24.9% | 30,861 | +17.9% | 0.00% | – |
Q3 2014 | $329,000 | +55.9% | 26,167 | +24.9% | 0.00% | – |
Q2 2014 | $211,000 | -35.1% | 20,942 | -13.6% | 0.00% | – |
Q1 2014 | $325,000 | – | 24,230 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
L1 Capital Pty Ltd | 1,050,124 | $10,312,000 | 3.31% |
Alambic Investment Management, L.P. | 19,934 | $196,000 | 2.15% |
INGALLS & SNYDER LLC | 1,363,603 | $13,391,000 | 0.92% |
ACUTA CAPITAL PARTNERS, LLC | 300,000 | $2,946,000 | 0.80% |
RA Capital Management | 1,858,474 | $18,250,000 | 0.33% |
Perceptive Advisors | 2,150,641 | $21,119,000 | 0.31% |
SPHERA FUNDS MANAGEMENT LTD. | 310,000 | $3,044,000 | 0.30% |
Eversept Partners, LP | 103,829 | $1,019,601 | 0.23% |
Opaleye Management Inc. | 100,000 | $982,000 | 0.19% |
GSA CAPITAL PARTNERS LLP | 58,095 | $570,000 | 0.10% |